CDXC, CEMI, and GERN are the stocks whose asset turnover ratios are most correlated with MYGN. Growth is the dimension where MYGN ranks best; there it ranks ahead of 74.41% of US stocks. We have 9 different ratings for every stock to help you appreciate its future potential. Sign Up NowGet this delivered to your inbox, and more info about our products and services.
Moody’s Daily Credit how to invest 1,000 dollars Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure. Myriad Genetics issued an update on its first quarter 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of -$0.20--$0.18 for the period, compared to the consensus EPS estimate of -$0.10.
Bloomberg Businessweek Highlights from a week-long virtual event bringing Bloomberg Businessweek magazine to life. Carol Massar and Tim Stenovec host a look back at the best interviews, discussions and more. Bloomberg Markets The Close Romaine Bostick breaks down the day's top stories and trading action leading into the close. Our clearing firm Apex Clearing Corp has purchased an additional insurance policy.
A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. The P/E ratio of Myriad Genetics is -16.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies. Several equities research analysts recently issued reports on the stock. Raymond James lifted their price objective on shares of Myriad Genetics from $25.00 to $27.00 and gave the company an “outperform” rating in a research note on Friday, March 3rd. StockNews.com assumed coverage on shares of Myriad Genetics in a research note on Thursday, March 16th.
The average price suggested by analysts for MYGN is $20.67, which is -$2.06 below the current market price. The public float for MYGN is 79.43M, and currently, shorts hold a 5.64% of that float. The average trading volume for MYGN on March 15, 2023 was 757.05K shares. In summary, Myriad Genetics Inc. has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.
12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees. Biden's disturbing new government program may be worse than Obama's.
Its specialists are interested in stocks that have been undervalued by different reasons. They are trying to find them, count their potential and bring them to their clients. Highlights important summary options statistics to provide a forward looking indication of investors' sentiment. The genetic-testing company announced an acquisition and lowered its guidance.
In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Myriad Genetics stock was originally listed at a price of $6.06 in Dec 31, 1997. If you had invested in Myriad Genetics stock at $6.06, your return over the last 25 years would have been 287.27%, for an annualized return of 5.57% . On August 13, 2019, Defendants disclosed that the FDA requested changes to GeneSight® and the Company had been in ongoing discussions with the FDA about the request.
The company issued revenue guidance of $170.00 million-$172.00 million, compared to the consensus revenue estimate of $174.88 million. According to analysts, Myriad Genetics's stock has a predicted upside of 17.52% based on their 12-month price targets. The Myriad Genetics 52-week low stock price is 13.92, which is 40.7% below the current share price. The Myriad Genetics 52-week high stock price is 28.18, which is 20% above the current share price.
The simple moving average for the last 20 days is 12.98% for MYGN stock, with a simple moving average of 13.09% for the last 200 days. The company was founded in 1991 and is based in Salt Lake City, Utah. The chart below shows how a company's share price and consensus price target have changed over time. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. Historical daily share price chart and data for Myriad Genetics since 1995 adjusted for splits.
https://1investing.in/ hereditary cancer testing volume registered strong growth in the fourth quarter. Real-time analyst ratings, insider transactions, earnings data, and more. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.
It’s calculated by averaging the closing stock price over the previous 50 trading days. In conclusion, Myriad Genetics Inc. has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company's dividend expressed as a percentage of its current stock price.
About Hagens BermanHagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw. According to the Complaint, Defendants misled investors about Myriad Genetics’ GeneSight®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. Class-action law firm urges MYGN investors who have suffered losses of $50K+ to submit your loss now to learn if they qualify to recover their investment losses.
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Humana (HUM – Research Report), Myriad Genetics (MYGN – Research Report) and Regeneron (REGN – Research Report). Myriad Genetics' latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation. Overall, this stock passed 6/33 due dilligence checks and has weak fundamentals, according to our automated analysis.